Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Arcaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | BLM | P54132 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.34 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL10783977 | 0.97 | ALOX15 (0.68) | ALOX15SMN1; SMN2MEN1KMT2ACYP1A2 | |
| Sulfuric Acid SCHEMBL11501592 | 0.97 | ALOX15 (0.68) | ALOX15SMN1; SMN2MEN1KMT2ACYP1A2 | |
| Sulfuric Acid SCHEMBL11277287 | 0.97 | ALOX15 (0.68) | ALOX15SMN1; SMN2MEN1KMT2ACYP1A2 | |
| Synthalin SCHEMBL2001776 | 0.97 | ALOX15 (0.68) | ALOX15SMN1; SMN2MEN1KMT2ACYP1A2 | |
| Sulfuric Acid SCHEMBL7641408 | 0.91 | ALOX15 (0.61) | ALOX15SMN1; SMN2MEN1KMT2ACYP1A2 | |
| Sulfuric Acid SCHEMBL9637045 | 0.91 | ALOX15 (0.61) | ALOX15SMN1; SMN2MEN1KMT2ACYP1A2 | |
| Agmatine SCHEMBL196302 | 0.91 | ALOX15 (0.61) | ALOX15SMN1; SMN2MEN1KMT2ACYP1A2 | |
| Agmatine SCHEMBL4535578 | 0.91 | ALOX15 (0.61) | ALOX15SMN1; SMN2MEN1KMT2ACYP1A2 | |
| Sulfuric Acid SCHEMBL17022790 | 0.91 | ALOX15 (0.61) | ALOX15SMN1; SMN2MEN1KMT2ACYP1A2 | |
| Iminoctadiene SCHEMBL5909614 | 0.91 | ALOX15 (0.61) | ALOX15SMN1; SMN2MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-04-30 | — | — | US | claimed |
| EP-2841067-A2 | A DRUG SCREENING PLATFORM FOR RETT SYNDROME | The Regents of The University of California (US) | 2015-03-04 | — | — | EP | claimed |
| WO-2013163455-A2 | A DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-31 | — | — | WO | claimed |
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-11 | — | — | US | disclosed |
| US-11213494-B2 | Compositions and methods for the treatment of pervasive development disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-01-04 | — | — | US | disclosed |
| US-10555916-B2 | NMDAR antagonist for the treatment of pervasive development disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-11 | — | — | US | disclosed |
| EP-3485882-A1 | COMPOSITIONS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | Case Western Reserve University (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-2948135-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2019-01-02 | — | — | EP | disclosed |
| US-20180008559-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-01-11 | — | — | US | disclosed |
| US-20150359759-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2015-12-17 | — | — | US | disclosed |
| EP-2948135-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | Case Western Reserve University (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-04-30 | — | — | US | disclosed |
| EP-2841067-A2 | A DRUG SCREENING PLATFORM FOR RETT SYNDROME | The Regents of The University of California (US) | 2015-03-04 | — | — | EP | disclosed |
| EP-1983051-B1 | Isolation and purification of nucleic acid molecules with solid phase | ROCHE DIAGNOSTICS GMBH (DE) | 2014-11-26 | — | — | EP | disclosed |
| WO-2014117089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-07-31 | — | — | WO | disclosed |
| WO-2013163455-A2 | A DRUG SCREENING PLATFORM FOR RETT SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-31 | — | — | WO | disclosed |
| EP-2338492-A1 | Methods and compositions for the treatment of alzheimer | Universidad del Pais Vasco (ES) | 2011-06-29 | — | — | EP | disclosed |
| EP-1983051-A2 | Isolation and purification of nucleic acid molecules with solid phase | Roche Diagnostics GmbH (DE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007029063-A2 | TREATMENT AND/OR PREVENTION OF PERVASIVE DEVELOPMENTAL DISORDERS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2007-03-15 | — | — | WO | disclosed |
| US-5253198-A | Three-dimensional optical memory | SYRACUSE UNIVERSITY (US) | 1993-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | GRIN2D, GRIN2A, GRIN2C | ALOX15 1269/4885SMN1; SMN2 933/4885MEN1 4460/4885 |
| US-20150119327-A1 | DRUG SCREENING PLATFORM FOR RETT SYNDROME | GRIN2A, GRIN1, GRIN2B | ALOX15 4379/4885SMN1; SMN2 410/4885MEN1 2707/4885 |
| US-20150359759-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | MECP2, GRIN2A, GRIN2C | ALOX15 4170/4885SMN1; SMN2 713/4885MEN1 4738/4885 |
| US-11213494-B2 | Compositions and methods for the treatment of pervasive development disorders | GRIN2A, GRIN2C, GRIN2D | ALOX15 2265/4885SMN1; SMN2 560/4885MEN1 4451/4885 |
| US-20180008559-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | GRIN2A, GRIN2C, GRIN2D | ALOX15 2265/4885SMN1; SMN2 560/4885MEN1 4451/4885 |
| US-10555916-B2 | NMDAR antagonist for the treatment of pervasive development disorders | MECP2, GRIN2A, GRIN2B | ALOX15 4441/4885SMN1; SMN2 905/4885MEN1 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.